# AxoGen

Type: Company (AXGN)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/axogen
Canonical HTML page: https://getfinancebrief.com/entity/axogen

## Recent coverage (2 stories)

### DAFNA Capital Trims Axogen Stake by $6.5M Following 71% Stock Surge
2026-03-22 04:28:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately 265,456 shares during the fourth quarter of 2025, a move valued at $6.53 million. Despite the trim, the hedge fund maintains a significant $15.6 million stake in the nerve-repair specialist, which has seen its stock price climb 71% over the past year.
Full story: https://getfinancebrief.com/story/dafna-capital-axogen-trim-analysis

### AxoGen Surges as Wells Fargo Issues Rare 'Strong-Buy' Rating Upgrade
2026-02-21 01:12:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AxoGen (NASDAQ: AXGN) has received a major boost from Wall Street as Wells Fargo upgraded the nerve-repair specialist to a 'Strong-Buy' rating. The upgrade follows a significant price target hike from Jefferies, signaling a robust consensus on the company's growth potential in the medical technology sector.
Full story: https://getfinancebrief.com/story/axogen-axgn-wells-fargo-strong-buy-upgrade

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.